AQR Capital Management LLC Has $165.48 Million Stock Position in Illumina, Inc. $ILMN

Key Points

• AQR Capital Management LLC significantly increased its position in Illumina, Inc. by 361.7%, owning over 2.1 million shares worth approximately $165.48 million at the end of the most recent quarter.
• Multiple institutional investors increased their stakes in Illumina, with Brown Advisory Inc. lifting its position by 52.1% and Vanguard Group Inc. acquiring 3.5% more shares, highlighting strong institutional interest in the company.
• Illumina's recent earnings report showed an EPS of $1.19, exceeding estimates, but revenue decreased by 4.8% year-over-year, indicating challenges despite robust fundamentals.

AQR Capital Management LLC increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 361.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,121,585 shares of the life sciences company's stock after buying an additional 1,662,093 shares during the period. AQR Capital Management LLC owned 1.34% of Illumina worth $165,484,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ILMN. Brown Advisory Inc. lifted its position in Illumina by 52.1% during the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock worth $230,818,000 after buying an additional 996,589 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Illumina by 2,057.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after purchasing an additional 879,533 shares during the period. Vanguard Group Inc. lifted its position in Illumina by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after purchasing an additional 558,243 shares during the period. Pacer Advisors Inc. lifted its position in Illumina by 2,292.9% during the 1st quarter. Pacer Advisors Inc. now owns 565,680 shares of the life sciences company's stock valued at $44,881,000 after purchasing an additional 542,040 shares during the period. Finally, Spyglass Capital Management LLC acquired a new position in Illumina during the 4th quarter valued at about $71,855,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on ILMN. Morgan Stanley upped their target price on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, August 4th. Barclays upped their target price on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research report on Friday, August 1st. Wall Street Zen downgraded shares of Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a research report on Tuesday. Finally, Daiwa America downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $123.06.

Illumina Price Performance

NASDAQ ILMN opened at $96.07 on Thursday. The business has a 50 day simple moving average of $99.47 and a 200 day simple moving average of $88.58. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market cap of $14.77 billion, a price-to-earnings ratio of 12.16, a PEG ratio of 2.25 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business's quarterly revenue was down 4.8% on a year-over-year basis. During the same period last year, the business earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.